# Empagliflozin in Patients With Glomerulonephritis

> **NCT05283057** · PHASE3 · COMPLETED · sponsor: **Kasr El Aini Hospital** · enrollment: 50 (actual)

## Conditions studied

- Glomerulonephritis
- Proteinuria

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05283057
- **Lead sponsor:** Kasr El Aini Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-20
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05283057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05283057, "Empagliflozin in Patients With Glomerulonephritis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05283057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*